BCM
CRDL

Brookstone Capital Management’s Cardiol Therapeutics CRDL Stock Holding History

Brookstone Capital Management’s Portfolio CRDL Stock Details CRDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-15,025
Closed -$20K – 787
2022
Q2 		$20K Buy
+15,025
New +$21.4K ﹤0.01% 750
2022
Q1 		– Sell
-15,887
Closed -$27K – 781
2021
Q4 		$27K Buy
+15,887
New +$43.9K ﹤0.01% 741

Other funds holding CRDL

MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
MHIC
Marble Harbor Investment Counsel Boston, Massachusetts $923M AUM 14.09% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
RSWM
Robertson Stephens Wealth Management San Francisco, California $3.57B AUM 28.36% 1-Year Est. Return

Brookstone Capital Management's CRDL Position: Q3 2022 in Review

Brookstone Capital Management sold out of Cardiol Therapeutics (CRDL) in Q3 2022, closing a stake of 15,025 shares — an estimated $20K sold.

Brookstone Capital Management first reported a position in CRDL in Q4 2021 and held it in 2 quarters. The position peaked at $27K in Q4 2021. 26 funds tracked by Wall St. Rank hold CRDL as of Q3 2022.

  • Brookstone Capital Management reported no remaining Cardiol Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Brookstone Capital Management sold 15,025 Cardiol Therapeutics shares in Q3 2022, an estimated $20K.
  • Brookstone Capital Management first reported a position in Cardiol Therapeutics in Q4 2021 and held it in 2 quarters.
  • Brookstone Capital Management's Cardiol Therapeutics position peaked at $27K in Q4 2021.
  • 26 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q3 2022.

Based on Brookstone Capital Management's 13F filing for Q3 2022, filed 14 Oct 2022.